Advaxis completes ADXS-HER2 pre-IND meeting with FDA Advaxis.

The FDA addressed the Company’s questions and provided guidance on the requirements to file an IND to initiate scientific trials. This IND is definitely expected to become submitted in the initial half of 2012. Inside our second pre-IND meeting of the entire year, the FDA stayed collegial, receptive, and useful as we consider the steps needed to expand our oncology pipeline, said Dr. John Rothman, EVP of Technology & Operations at Advaxis.. Advaxis completes ADXS-HER2 pre-IND meeting with FDA Advaxis, Inc., , a leader in developing the next generation of immunotherapies for tumor and infectious illnesses, completed a pre-IND ending up in the FDA on November 22, 2011 to discuss the development arrange for ADXS-HER2, an immunotherapy for the treating HER2 expressing cancers.Jackson Basis for the Advancement of Army Medicine, Inc. possess entered right into a Cooperative Research and Development Contract to extend their collaborative endeavors in prostate disease study. The purpose of the joint analysis will be to differentiate individuals with favorable versus poor prognosis during diagnosis and primary treatment using definitive genetic markers. The majority of prostate cancer instances in PSA-screened population fall into a therefore called grey zone of prostate malignancy where outcome is incredibly difficult to predict at the time of medical diagnosis. The CRADA extends a long and already fruitful collaboration with USU’s Middle for Prostrate Disease Research .